Skip to main content
. Author manuscript; available in PMC: 2015 Nov 6.
Published in final edited form as: Cell Stem Cell. 2014 Oct 9;15(5):605–618. doi: 10.1016/j.stem.2014.09.008

Figure 5. hepPDs revert back to hepatocyctes in vivo.

Figure 5

A) Fah+/+ ROSA-mTmG Sox9-CreERT2 hepatocytes were transplanted into Fah−/− recipients to generate chimeras. DDC injury was given to repopulated chimeras for 4 weeks, a low dose pulse of tamoxifen was given (15mg/kg), and injury was continued for 2 additional weeks. B) Tissue harvested by 1/3 partial hepatectomy showed most Sox9-CreERT2 marked (mGFP+) cells co-localized with A6 antigen (arrowhead). C) Low-power view shows Sox9-marked ductal cells in periportal zone. D) Sox9-CreERT2- marked cells have biliary morphology that do not co-localize with hepatocyte marker FAH. E) Following a 4-week recovery period, mGFP+ hepatocytes localized in the portal area. F) Upon healing Sox9-CreERT2 marked cells assumed hepatocyte morphology co-localized with FAH (arrow). G) Within animal comparison indicated that recovery from DDC injury was associated with a 5-fold increase in marked hepatocytes (6.6% versus 33.5%, p < 0.01**, paired t-test, n=4).